4th Annual Meeting

ERIA
European Research Initiative on ALK-related Malignancies

June 27 – 28, 2013
NCT-Building
Im Neuenheimer Feld 460
69120 Heidelberg
Conference Room K2/K3, 2nd Floor
The European Research Initiative on ALK-related malignancies (ERIA) was conceived at the American Association for Cancer Research 100th Annual Meeting in Denver, CO, USA back in 2009 by Suzanne Turner, Olaf Merkel and Lukas Kenner. Our aim is to strengthen cooperation and partnership of European research groups focused on ALK-related malignancies in order to accelerate scientific progress. With this aim in mind we anticipate that more efficacious and less toxic therapeutic strategies will be developed.

The meeting will be held at the National Center of Tumor Diseases (NCT) in Heidelberg. NCT is a joint project of the German Cancer Research Center (DKFZ), Heidelberg University Hospital jointly with the Medical Faculty of Heidelberg University and German Cancer Aid (Deutsche Krebshilfe). It is a modern oncology center modeled after Comprehensive Cancer Centers in the U.S.A. and Scandinavia. NCT’s key asset is its comprehensive interdisciplinary approach, which takes account of all aspects that are relevant in the fight against cancer.
The European Research Initiative on ALK-related malignancies (ERIA) was conceived at the American Association for Cancer Research 100th Annual Meeting in Denver, CO, USA back in 2009 by Suzanne Turner, Olaf Merkel and Lukas Kenner. Our aim is to strengthen cooperation and partnership of European research groups focused on ALK-related malignancies in order to accelerate scientific progress. With this aim in mind we anticipate that more efficacious and less toxic therapeutic strategies will be developed.

The meeting will be held at the National Center of Tumor Diseases (NCT) in Heidelberg. NCT is a joint project of the German Cancer Research Center (DKFZ), Heidelberg University Hospital jointly with the Medical Faculty of Heidelberg University and German Cancer Aid (Deutsche Krebshilfe). It is a modern oncology center modeled after Comprehensive Cancer Centers in the U.S.A. and Scandinavia. NCT’s key asset is its comprehensive interdisciplinary approach, which takes account of all aspects that are relevant in the fight against cancer.

**Thursday, 27th June**

14:45 Arrival and coffee

15:00 Introductory remarks

  **Session 1:**
  
  Chair: Giorgio Inghirami, Suzanne Turner

15:05 **Anaplastic large cell lymphoma-past and future**
Giorgio Inghirami, Torino, Italy

15:35 **Using switchable mouse genetics to find the best targets for treating cancer**
Gerard Evan, Cambridge, UK

16:05 **Autologous, Allogenic or no stem cell transplantation: Results of the European ALCL-Relapse Study**
Wilhelm Wössmann, Giessen, Germany

16:35 Coffee

  **Session 2:**
  
  Chair: Stefan Fröhling, Olaf Merkel

16:45 **T-cell biogenesis and T-cell lymphomas**
Hans-Reimer Rodewald, Heidelberg, Germany

17:15 **The ALK kinase in neuroblastoma**
Ruth Palmer, Umea, Sweden

17:45 **ALK mutations and mechanisms of transformation in neuroblastoma**
Tom Look, Boston, USA

14:45 4th Annual Meeting
European Research Initiative on ALK-related Malignancies

Thursday, 27th June

14:45 Arrival and coffee

15:00 Introductory remarks

  **Session 1:**
  
  Chair: Giorgio Inghirami, Suzanne Turner

15:05 **Anaplastic large cell lymphoma-past and future**
Giorgio Inghirami, Torino, Italy

15:35 **Using switchable mouse genetics to find the best targets for treating cancer**
Gerard Evan, Cambridge, UK

16:05 **Autologous, Allogenic or no stem cell transplantation: Results of the European ALCL-Relapse Study**
Wilhelm Wössmann, Giessen, Germany

16:35 Coffee

  **Session 2:**
  
  Chair: Stefan Fröhling, Olaf Merkel

16:45 **T-cell biogenesis and T-cell lymphomas**
Hans-Reimer Rodewald, Heidelberg, Germany

17:15 **The ALK kinase in neuroblastoma**
Ruth Palmer, Umea, Sweden

17:45 **ALK mutations and mechanisms of transformation in neuroblastoma**
Tom Look, Boston, USA
The European Research Initiative on ALK-related malignancies (ERIA) was conceived at the American Association for Cancer Research 100th Annual Meeting in Denver, CO, USA back in 2009 by Suzanne Turner, Olaf Merkel and Lukas Kenner. Our aim is to strengthen cooperation and partnership of European research groups focused on ALK-related malignancies in order to accelerate scientific progress. With this aim in mind we anticipate that more efficacious and less toxic therapeutic strategies will be developed.

The meeting will be held at the National Center of Tumor Diseases (NCT) in Heidelberg. NCT is a joint project of the German Cancer Research Center (DKFZ), Heidelberg University Hospital jointly with the Medical Faculty of Heidelberg University and German Cancer Aid (Deutsche Krebshilfe). It is a modern oncology center modeled after Comprehensive Cancer Centers in the U.S.A. and Scandinavia. NCT’s key asset is its comprehensive interdisciplinary approach, which takes account of all aspects that are relevant in the fight against cancer.

---

**Friday, 28th June**

**Session 3: Therapeutic Strategies for ALCL**  
Chair: Mathias Witzens-Harig, Sylvie Giuriato

- **9:00** Update on the Crizotinib trial in ALCL  
  Carlo Gambacorti-Passerini, Milano-Bicocca, Italy

- **9:20** Early Assessment of Minimal Residual Disease by Qualitative PCR for NPM-ALK Identifies Patients at Very High Risk of Relapse in Anaplastic Large Cell Lymphoma  
  Christine Damm-Welk, Giessen, Germany

- **9:40** Autophagy: new therapeutic target in ALK lymphoma?  
  Sylvie Giuriato, Toulouse, France

- **10:00** Detection of anti-NPM-ALK T cells in children with NPM-ALK-positive anaplastic large cell lymphoma  
  S. Werner, V. Singh, Giessen, Germany

- **10:20** ALK as a target for immunotherapy  
  Roberto Chiarle, Boston, USA

- **10:40** Coffee

**Session 4: Aberrant T-cell signaling**  
Chair: Lukas Kenner Thorsten Zenz

- **11:00** Role of miR-155 in T-cell lymphomas  
  Olaf Merkel, Heidelberg Germany

- **11:20** Activation of proto-oncogenes in human malignancies  
  Stephan Mathas, Berlin, Germany

- **11:40** Interplay between p53 and ALK-kinase  
  George Rassidakis, Athens, Greece

- **12:00** The biological role of the tyrosine phosphorylation of the RNA-binding HuR in ALK-depandent tumors  
  Estelle Espinos, Toulouse, France

- **12:20** Buffet Lunch

**Session 5: Lymphomagenesis**  
Chair: Olaf Merkel, Estelle Espinos

- **14:00** A new transgenic mouse model for T cell lymphoma / leukemia in the CD8 T cell lineage  
  Richard Moriggl, Vienna, Austria

- **14:20** Modelling the development of T-cell lymphoma  
  Suzanne Turner, Cambridge, England

- **14:40** Coffee and Discussion
Organisers
Olaf Merkel, Suzanne Turner, Lukas Kenner, Thorsten Zenz

Host Institutions
National Center of Tumor Diseases (NCT)
German Cancer Research Center (DKFZ)
Heidelberg, Germany

Venue
NCT-Building
Im Neuenheimer Feld 460, 69120 Heidelberg
Conference Room K2 / K3, 2nd floor

Information / Contact
Ingrid Schamal
Nationales Centrum für Tumorerkrankungen
Heidelberg (NCT)
Im Neuenheimer Feld 460, 69120 Heidelberg
Phone 06221/56 65 58, Fax: 06221/56 50 94
E-Mail: hso@nct-heidelberg.de
http://www.erialcl.net/

No Registration Fee

Education credits
For this event five points for continuing education are submitted by the Landesärztekammer Baden Württemberg
With the support of

Im Neuenheimer Feld

Bus-Stop: Studentenheim

How to get to the NCT (meeting venue):

From Train Station:
Bus 32 (Neuenheimer Feld), exit at stop Studentenheim (50 m from NCT)

From Bismarckplatz:
Bus 31 (Neuenheimer Feld), exit at stop Studentenheim

From Kulturbrauerei:
Bus 33 (stop Alte Brücke), exit at Bismarckplatz and change to Bus 31, exit at stop Studentenheim